ProVise Management Group’s Sanofi SNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.15M Sell
120,829
-112,748
-48% -$5.04M 0.35% 68
2026
Q1
$11.3M Buy
233,577
+9,155
+4% +$427K 0.81% 42
2025
Q4
$10.9M Buy
224,422
+13,891
+7% +$689K 0.77% 45
2025
Q3
$9.94M Buy
210,531
+10,135
+5% +$489K 0.73% 47
2025
Q2
$9.68M Buy
200,396
+7,183
+4% +$367K 0.76% 44
2025
Q1
$10.7M Buy
193,213
+5,786
+3% +$313K 0.91% 38
2024
Q4
$9.04M Buy
187,427
+733
+0.4% +$37.3K 0.77% 39
2024
Q3
$10.8M Buy
186,694
+9,966
+6% +$538K 0.85% 35
2024
Q2
$8.57M Buy
176,728
+5,509
+3% +$266K 0.73% 40
2024
Q1
$8.32M Buy
171,219
+10,187
+6% +$497K 0.72% 43
2023
Q4
$8.01M Buy
161,032
+8,554
+6% +$418K 0.68% 42
2023
Q3
$8.18M Buy
152,478
+3,552
+2% +$189K 0.76% 39
2023
Q2
$8.03M Sell
148,926
-2,043
-1% -$110K 0.73% 39
2023
Q1
$8.22M Sell
150,969
-14,662
-9% -$713K 0.79% 39
2022
Q4
$8.02M Sell
165,631
-12,540
-7% -$550K 0.81% 36
2022
Q3
$6.77M Buy
178,171
+966
+0.5% +$43K 0.76% 40
2022
Q2
$8.87M Buy
177,205
+3,249
+2% +$172K 0.95% 32
2022
Q1
$8.93M Buy
173,956
+2,382
+1% +$123K 0.84% 37
2021
Q4
$8.6M Buy
171,574
+9,257
+6% +$458K 0.78% 33
2021
Q3
$7.83M Buy
162,317
+8,885
+6% +$452K 0.77% 32
2021
Q2
$8.08M Sell
153,432
-3,070
-2% -$160K 0.82% 31
2021
Q1
$7.74M Sell
156,502
-1,249
-0.8% -$60K 0.83% 28
2020
Q4
$7.67M Sell
157,751
-210
-0.1% -$10.4K 0.88% 27
2020
Q3
$7.92M Sell
157,961
-492
-0.3% -$25.3K 1.06% 22
2020
Q2
$8.09M Sell
158,453
-8,659
-5% -$421K 1.16% 18
2020
Q1
$7.31M Sell
167,112
-5,326
-3% -$255K 1.23% 18
2019
Q4
$8.66M Buy
172,438
+4,313
+3% +$202K 1.07% 25
2019
Q3
$7.79M Buy
168,125
+44,572
+36% +$1.92M 1.03% 25
2019
Q2
$5.35M Buy
123,553
+4,242
+4% +$180K 0.72% 39
2019
Q1
$5.28M Sell
119,311
-14,870
-11% -$637K 0.74% 39
2018
Q4
$5.83M Sell
134,181
-7,012
-5% -$309K 0.92% 31
2018
Q3
$6.31M Sell
141,193
-2,067
-1% -$88.3K 0.83% 33
2018
Q2
$12.9M Sell
143,260
-435
-0.3% -$17.1K 0.97% 31
2018
Q1
$5.76M Buy
143,695
+9,345
+7% +$389K 0.85% 33
2017
Q4
$5.78M Sell
134,350
-11,838
-8% -$546K 0.83% 32
2017
Q3
$7.28M Buy
146,188
+15,675
+12% +$758K 1.06% 24
2017
Q2
$6.25M Buy
130,513
+50,175
+62% +$2.4M 0.95% 28
2017
Q1
$3.63M Buy
80,338
+37,375
+87% +$1.59M 0.58% 51
2016
Q4
$1.74M Buy
42,963
+3,017
+8% +$119K 0.3% 99
2016
Q3
$1.53M Sell
39,946
-3,684
-8% -$148K 0.26% 107
2016
Q2
$1.83M Buy
43,630
+625
+1% +$25.6K 0.34% 91
2016
Q1
$1.73M Sell
43,005
-1,449
-3% -$58.2K 0.35% 84
2015
Q4
$1.9M Sell
44,454
-276
-0.6% -$12.7K 0.4% 78
2015
Q3
$2.12M Buy
44,730
+1,800
+4% +$91.7K 0.49% 62
2015
Q2
$2.13M Buy
42,930
+1,100
+3% +$55.7K 0.45% 66
2015
Q1
$2.07M Buy
41,830
+4,900
+13% +$234K 0.44% 66
2014
Q4
$1.68M Buy
36,930
+367
+1% +$17.8K 0.36% 85
2014
Q3
$2.06M Sell
36,563
-6,518
-15% -$350K 0.45% 66
2014
Q2
$2.29M Buy
43,081
+125
+0.3% +$6.63K 0.5% 55
2014
Q1
$2.25M Buy
42,956
+800
+2% +$40.5K 0.54% 51
2013
Q4
$2.26M Sell
42,156
-325
-0.8% -$16.8K 0.58% 50
2013
Q3
$2.15M Buy
42,481
+2,325
+6% +$118K 0.61% 37
2013
Q2
$2.07M Buy
+40,156
New +$2.14M 0.61% 41

Other funds holding SNY

ProVise Management Group's SNY Position: Q2 2026 in Review

ProVise Management Group reduced its Sanofi (SNY) stake by 48% in Q2 2026, selling an estimated $5.04M and leaving 120,829 shares worth $5.15M. The position accounts for 0.35% of the portfolio, ranked #68.

ProVise Management Group first reported a position in SNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $12.9M in Q2 2018. 716 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

  • ProVise Management Group held 120,829 shares of Sanofi worth $5.15M as of Q2 2026.
  • ProVise Management Group sold 112,748 Sanofi shares in Q2 2026, an estimated $5.04M.
  • Sanofi made up 0.35% of ProVise Management Group's portfolio in Q2 2026, its #68 holding.
  • ProVise Management Group first reported a position in Sanofi in Q2 2013 and has held it in 53 quarters since.
  • ProVise Management Group's Sanofi position peaked at $12.9M in Q2 2018.
  • 716 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on ProVise Management Group's 13F filing for Q2 2026, filed 3 Aug 2026.